Ibrance and Kaolin cephalin clotting time prolonged - a phase IV clinical study of FDA data

Summary:

We study 104,477 people who take Ibrance (palbociclib) or have Kaolin cephalin clotting time prolonged. No report of Kaolin cephalin clotting time prolonged is found in people who take Ibrance.

The phase IV clinical study is created by eHealthMe based on reports from the FDA, and is updated regularly.

What is Ibrance?

Ibrance has active ingredients of palbociclib. eHealthMe is studying from 104,434 Ibrance users. Check the latest studies of Ibrance.

What is Kaolin Cephalin Clotting Time Prolonged?

Kaolin cephalin clotting time prolonged is found to be associated with 1 drug and 68 conditions by eHealthMe. Check the latest studies of Kaolin cephalin clotting time prolonged.

On Apr, 22, 2026

No report is found.

Do you take Ibrance and have Kaolin cephalin clotting time prolonged?

- Check whether Kaolin cephalin clotting time prolonged is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Ibrance:

Ibrance (104,434 reports)

Kaolin cephalin clotting time prolonged treatments and more:

Kaolin cephalin clotting time prolonged (43 reports)

How severe was Kaolin cephalin clotting time prolonged and when was it recovered:

Kaolin cephalin clotting time prolonged in Ibrance

Expand to all the drugs that have ingredients of palbociclib:

Kaolin cephalin clotting time prolonged and drugs with ingredients of palbociclib

Browse all side effects of Ibrance:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Kaolin cephalin clotting time prolonged:

Kaolin cephalin clotting time prolonged

Browse all the conditions that are associated with Kaolin cephalin clotting time prolonged:

Kaolin cephalin clotting time prolonged

How the study uses the data?

The study uses data from the FDA. It is based on palbociclib (the active ingredients of Ibrance) and Ibrance (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.